Navigation Links
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/13/2010

SAN DIEGO, Sept. 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Stifel Nicolaus Annual Healthcare Conference on Friday, September 17, 2010 at 8:35 a.m. EDT (5:35 a.m. PDT).  The conference is being held at the Four Seasons in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs.

Dr. Worland will also present a Company overview at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 12:30 p.m. EDT (9:30 a.m. PDT).  The conference is being held at the Grand Hyatt New York.  

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com.  Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software.  A replay of the presentation at the Stifel Nicolaus Annual Healthcare Conference will be available approximately one hour after the live webcast concludes and will be available through October 1, 2010.  A replay of the presentation at the UBS Global Life Sciences Conference will be available approximately one hour after the live webcast concludes and will be available through October 6, 2010.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a direct-acting antiviral or DAA, for the treatment of hepatitis C. In an ongoing Phase II study, the Company has completed 12 weeks of dosing ANA598 added to current standard of care. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended June 30, 2010.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 According to a new market ... - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast ... U.S. was valued at US$ 5.89 Bn in 2014 and ... 2015 to 2023 to reach US$ 7.99 Bn in 2023. ... emerging needle free drug delivery devices and the market is ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
(Date:5/26/2016)... Massachusetts , May 26, 2016 ... (NGS) has matured into an essential life science tool ... and development applications. BCC Research reveals in its new ... a second growth phase, one powered by a range ... fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) ...
Breaking Medicine Technology:
(Date:5/28/2016)... AL (PRWEB) , ... May 28, 2016 , ... May ... US Open Martial Arts Fighting Challenge with theme event of “K Warriors” on June ... Mobile, AL 36608. , The event is sponsored and hosted by Shaolin Institute ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... The award recognizes businesswomen who excel in their fields and who have made significant ... Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director of ...
(Date:5/27/2016)... ... May 27, 2016 , ... An educational campaign aimed at ... stories, courtesy of awareness-driven celebrities and thought leaders. It also provides insight to ... industry leaders such as Bioness. , As patients feel increasingly concerned about ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each ... studying complementary medicine. Allison Outerbridge is this year’s Life University winner ... 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
Breaking Medicine News(10 mins):